

5 C1-INH as a drug for treating viruses pathogenic to humans

The C1 esterase inhibitor (C1-INH) from human plasma is a sialic-acid-containing glycoprotein which can bind other glycoproteins and glycolipids which may be components or even membrane components of microorganisms of viral and bacterial origin. In accordance with the invention, this binding can inhibit the penetration of certain viruses into target cells.

The interaction between HIV and C1-INH has already been described and is used by the authors to separate HIV from a liquid (EP 0 966 976 A1 / Centeon Pharma GmbH) or, using a specially modified C1-INH molecule, to block the infectivity of HIV (EP 0 969 017 A1 / Centeon Pharma GmbH).

The first evidence has now been found that C1-INH is capable of reacting with influenza virus (IV) particles. The sialic groups of the considerable C1-INH carbohydrate fraction could be involved in this interaction as a multivalent receptor for viral haemagglutinin membrane components of, for example, orthomyxoviruses (such as influenza A and B viruses) or paramyxoviruses (e.g. parainfluenza, mumps and measles viruses); C1-INH would thus become, in the mucosa, a constituent of an early acting defence system against infectious organisms. After all, the haemagglutinin molecule has, in the distal globular domain, a binding site which identifies and can bind sialic acid molecules on the surface of infectable cells. This component has not previously been described for the lentiviruses (retroviruses) HIV-1 and HIV-2; for this reason the C1-INH/HIV interaction should involve other groupings.

Surprisingly, however, evidence of a C1-INH/HIV interaction was also found, for

example, after the treatment of C1-INH with neuraminidase.

Moreover, it is conceivable that C1-INH can inhibit the trypsin-like furin protease which splits the haemagglutinin precursor protein into two fragments linked by a disulfide bridge, a requirement for the fusogenic activity of the virus particles.

C1-INH is synthesized predominantly in the liver but also in epithelial cells and macrophages. Its plasma concentration is 25 mg/dl, the carbohydrate fraction 35%, of which 14% is sialic acid. Including a peptide fraction of 65%, its molecular weight is 104,000 (Haupt H. et al., 1970; Eur. J Biochem 17: 254).

The high carbohydrate fraction above all determines the occurrence and interactions with lectins. The multifunctional protein is found in the mucosa of the respiratory tract as a first barrier to infectious agents.

Functionally, C1-INH belongs to the class of serine proteinase inhibitors. Its spectrum of activity includes regulation of contact factors in haemostasis: F XI a, F XII a, F XII fragment and the plasma kallikrein associated with it. In addition, C1-INH controls, via the inhibition of C1 esterase, the classic complement activation pathway (Heimburger N., 1975, Proteinase inhibitors of human plasma – their properties and control functions. In: Proteases and Biological Control; ed. Reich E., et al., 367; Cold Spring Harbor Symp.; Heimburger N., 1994, Haemostasologie 14 (1): 1). Since it is the only complement inhibitor produced by the body, it plays a major clinical role, particularly since it is known that several fulminant disease processes occur via activation systems controlled by C1-INH. This gives rise to consumption of the inhibitor which often can be offset only by replacing it. That applies to the angioneurotic syndrome (after Quincke, 1882; now called angio-oedema) which is caused by a congenital deficiency of functional C1-INH, and to a number of other indications which have been added in recent years. The plasma-fractionating industry has responded to this need by manufacturing highly purified C1-INH concentrates. Recombinant human C1-INH is also available from several

sources (Davis A.E. et al., 1992 Natur Genetics: 1: 354); at present, however, this product does not contain a carbohydrate fraction which corresponds to the molecule occurring in human plasma and which for this reason cannot possess certain functions of the carbohydrate fraction of plasma-based C1-INH.

5

C1-INH has such broad therapeutic importance mainly because it regulates and limits the inflammation process locally, however it is caused. This applies in particular to the mucosa. Contact factors can react sensitively to any change in endothelial surfaces, e.g. by activating haemostasis, fibrinolysis and the
10 complement system. This gives rise, among other things, to bradykinin-type vasoactive peptides which influence vascular tone. In the capillary region this can lead to dilation and increased permeability which can cause oedema or even capillary leak syndrome (Eisele B. et al., 1994, "Die gelben Hefte", vol. XXXIV, issue 4: 162). If C1-INH does not limit this process at an early stage by
15 neutralization of the proteinases involved, it can spread to the organs in the form of general inflammation. That explains why C1-INH is used in so many syndromes such as capillary leak and circulatory shock (EPA 0586 909 A 2 / Behringwerke AG), sepsis and septic shock [EP 0620406 B 1 / Behringwerke AG) and in the extracorporeal circulation (DE-A-4227762 / Behringwerke AG).

20

What is new is that C1-INH not only inactivates proteinases involved in infection and inflammation but also interacts with viruses distinguishable from HIV by means of molecular regions other than the ones involved there and potentially neutralizes them. This reactivity could for example have a special importance in acute mumps
25 or measles infections. C1-INH is therefore a suitable means of alleviating the severity and consequences of acute measles or mumps infections. Neutralization evidently does not occur with the unchanged, native C1-INH molecule in relation to human immunodeficiency viruses (EP 0 969 017 A 1 / Centeon Pharma GmbH), which is why a specific modification was proposed.

30

Finally, there is evidence that the mucus of healthy individuals contains epithelial-cell-based glycoproteins which, "like cell receptors, bind virus particles and prevent infection". (Lange W., Vogel G., F. Uphoff H., 1999, Influenza Virologie, Epidemiologie, Klinik, Therapie und Prophylaxe; Blackwell Wissenschafts-Verlag).

5 Virus particles means influenza viruses (IV). Since many proteins were first isolated from human plasma at the Behringwerke, we tried to identify the glycoprotein(s).

We used IV for the model studies. Since we did not want to work with live viruses,
10 we selected a widely used vaccine which is declared as a chemically inactivated subunit, mixed vaccine containing 45 µg haemagglutinin in an application volume of 0.5 ml (Begrivac®). We could not detect any immunogen in the IV suspension using either Ouchterlony's agar gel diffusion technique or precipitating anti-IV antibodies. We were however able to do so after making a small modification (Fig. 1): the
15 central hole in the agar plate was initially filled with the vaccine and 24 hours later with a C1-INH solution in order to dissolve the IV antigens out of their interactions in the vaccine and to determine them.

To this end the punched holes arranged in a circle around the central hole were
20 filled separately with pooled human plasma and 2 polyclonal human immunoglobulin concentrates (Beriglobin® P) containing antibodies to IV. All showed, probably dependent on the antibody titre, 2 more or less sharply defined precipitates. The vaccine thus contains at least 2 antigen populations which both bind C1-INH (as is visible in Fig. 1) and differ in their molecular-weight-dependent
25 rate of diffusion. Detection of antigens from the vaccine is concentration-dependent and begins at 62.5 µg/ml C1-INH with 90 µg/ml haemagglutinin. It is not possible to give more accurate information using this technique. The immunoprecipitates in the agar gel are usually so fine that they are visible only after staining with Coomassie brilliant blue.

In immunoelectrophoresis, the subunit vaccine migrates heterogeneously in the β - to α 2-globulin region without forming a typical precipitate arc (Fig. 2 a). After the addition of C1-INH in 20-fold excess, the IV antigens concentrate in the α 2 region, trailing off at the site of application. The material precipitates over the entire region even with antibodies to C1-INH, in the form of an extension to the sickle-shaped precipitate formed by the C1-INH alone (Fig. 2 b).

From the findings it follows that the subunit vaccine, because of its splitting and chemical inactivation, consists of components with differing electrophoretic mobility which all bind to C1-INH and all have the same suitable acceptor. The main component, which probably contains haemagglutinins, forms complexes with α 2-globulin mobility. In addition, several higher-molecular-weight, more slowly migrating complexes and aggregates are visible. The striking thing is that the C1-INH/IV antigen complexes with antibodies to C1-INH are much more clearly visible than with anti-IV antibodies. This phenomenon may arise because C1-INH, which is potentially multivalent as regards IV, carries a large number of terminal sialic acid groups via which it can bind and perhaps even cross-link IV and other haemagglutinin-containing viruses, as a result of which epitopes recognizable by anti-IV antibodies could be blocked.

It was important to investigate the significance of sialic acid groups for the C1-INH/IV antigen interaction. To this end, treatment with test neuraminidase (test NA, Dade Behring) from *Vibrio colerae* (VC) was performed at pH 7.0 (optimum pH at about 5.5-6.0); this was done either before or after adding the vaccine to the C1-INH. Immunoelectrophoresis illustrates that the neuraminidase treatment (Fig. 3b) or the C1-INH/IV antigen complex formation reduce the mobility of the C1-INH to a comparably large extent (Fig. 3d) and that the two effects are additive (Fig. 3c), evidently without having any effect on the sequence of enzyme treatment (see Fig. 3c with 3f). It is also worth noting that C1-INH binds IV antigens even after neuraminidase treatment (Fig. 3c) and gives off the preformed complex neuraminic acid. This finding is consistent with the reversibility of C1-INH/IV antigen

complexing and with the existence of binding sites other than haemagglutinin on the C1-INH.

One possible candidate was NA, and specifically its active centre (AC). To find out if this was the case, we performed binding studies in the presence of a specific, synthetic NA inhibitor which sterically blocks the AC of IV-NA, thus preventing IV replication: Tamiflu® (Roche).

Fig. 4 shows the immunoelectrophoretic characterization of C1-INH (4a) and of the complex with IV vaccine (4b) which, surprisingly, does not form in the presence of Tamiflu® (4c). If an NA isolated from VC (VC-NA) is added to this sample set-up (4c), the antiserum to C1-INH which was used for this entire series of experiments shows a precipitate which runs into the site of application; it is identical to the VC-NA complex (4d). This is also seen in the set-up (4e) in which NA from IV and VC were preincubated together before C1-INH and Tamiflu® were added. As the result shows, the soluble bacterial NA binds better to C1-INH than the particulate IV-NA.

Conclusion: If the AC of IV-NA is blocked by Tamiflu®, the complex with C1-INH does not form. Both inhibitors evidently have the same target on the IV, but the synthetic inhibitor binds the AC of NA with higher affinity. And that should also be the 2nd binding site for C1-INH. On the basis of the reaction type, this bond should be stronger than that of the haemagglutinins to the neuraminic acid groups of the C1-INH.

According to these results, C1-INH acts as a competitive NA inhibitor; it is not specific like Tamiflu® but inhibits the NA from viruses and bacteria without regard to species (Fig. 4 d and e). What we know about the importance of NA inhibitors we know in part from the influenza viruses: they bind viruses, transport them – probably in a noninfectious form – present them to the immune cells and prevent reproduction. This type of inhibitor was, far-sightedly, classified by Burnet as a “competitive poison” as long ago as 1948 (Gubareva LV et al., Lancet 2000; 355:

827).

As regards the properties and identity of the inhibitor, with C1-INH there is no doubt. If human plasma with and without the addition of VC-NA is tested by immunoelectrophoresis with an antiserum to C1-INH, the VC-NA/C1-INH complex is found directly at the site of application; an antiserum to the inter- α -trypsin inhibitor shows that the homologous protein also contains neuraminic acid: after the addition of NA, it migrates little, but does so much more slowly (Fig. 5).

Tests with citrated or EDTA plasma underline the importance of Ca^{2+} ions. Immunoelectrophoresis in the presence of these complexing agents does not yield any direct evidence of visible precipitates with reduced mobility (Fig. 6). This is shown above all by comparison with the plasma-free system (Fig. 7). It is however noticeable that the addition of the vaccine leads to weaker formation of precipitates characteristic of the free (non-complexed) C1-INH; this points to a consumption reaction which is not initially visible.

However, after staining the agar gels it becomes clear that C1-INH/IV antigen complexes can even be formed in the citrated medium in which predominantly free, non-protein-bound Ca^{2+} ions are complexed; this does not happen at all in the presence of EDTA (Fig. 7, 3a-c).

It is noticeable that the citrated plasma already contains IV-C1-INH complexes in situ. The precipitate becomes stronger after the addition of IV, and after incubation at 37°C it is also apparent that it communicates with the free C1-INH (Fig. 7, 2 c).

We had the first evidence of the existence and incidence of these complexes in citrated plasma even earlier (Fig. 8): they are formed as variable amounts of precipitate, comparable to a plaque, when the agar gel is developed with antisera to C1-INH and/or to IV antigens. If IV vaccine is added to a citrated plasma of this kind, the concentration of free C1-INH decreases, whereas the plaque gets bigger.

A substantial addition to our findings was that the formation of IV/C1-INH complexes is reversible and dependent on Ca^{2+} ions: thus, complexes are formed in an IV-containing EDTA plasma if it is dialysed against a citrate solution with
5 5 mM CaCl_2 and 0.9% (m/v) NaCl.

Surprisingly, IV antigens can be detected in human plasma by immuno-electrophoresis. In 4 different human plasma pools investigated by us, we found, with human anti-IV antibodies, a punctiform, slowly diffusing antigen in the $\alpha 2$ -
10 globulin region (Fig. 8) and sometimes, further towards the anode, a soft, sickle-shaped precipitate (not visible in Fig. 8). The origin of the two IV antigens, which clearly circulate as a complex with C1-INH in the blood, is unclear; either they are from an influenza infection, or they are the result of vaccination. At any rate, according to their electrophoretic mobility, they could be processing products of IV.

15

After the addition of subunit influenza vaccine to the same plasma pool, a large, intensely coloured precipitate appears anodally to the site of application (Fig. 8a, bottom); it can be attributed to antigens present in the vaccine which partially correspond in their charge-dependent diffusion characteristics to the IV antigens
20 already present in the plasma. That can be seen even more clearly in immuno-electrophoreses of the two plasma pool samples which were developed with an antiserum to C1-INH (Fig. 8b). Wherever IV antigen is present in Fig. 8a, C1-INH is also found, together with, of course, the sickle-shaped precipitates of C1-INH which has not bound IV antigen. It is noticeable that the C1-INH is reduced in the
25 vaccine-enriched plasma; it is obviously bound by the vaccine (Fig. 8b bottom).

This view is also supported by the high colour intensity characteristic of IV/C1-INH complexes which is what makes possible their detection in high dilution in human plasma.

30

It is quite conceivable that the C1-INH/IV complexes can also be detected using

other technologies: for example, by a sandwich ELISA method by means of specific capture antibodies immobilized on a suitable matrix against one of the two components and using a second, marked antibody against the other component. The classic, relatively simple gel precipitation methods used have however proved
5 sufficient.

Diagnostically, the interaction of C1-INH with pathogenic agents could be potentially important, because the quantitative detection of, for example, C1-INH bound to virus particles or virus constituents might correspond to a particular infection status.

10 Our investigations were prompted by the observation mentioned earlier (by Lange, W. et al.; see above) that the mucous membrane contains glycoproteins which form an initial barrier in the defence against infections; they bind IV particles and thus inhibit infection.

15 We have identified C1-INH as one of the glycoproteins and, after tests with this model vaccine, can confirm that it has the ability to bind IV:

- 20 1. IV antigens as inhibitor complexes with varying diffusion capabilities can be detected concentration-dependently from an IV vaccine with C1-INH by means of suitable antibodies (Fig. 1).
- 25 2. In the electrical field used in immunoelectrophoresis, the vaccine migrates from the site of application to the α 2-globulin region. In doing so, it dissociates into many components of varying mobility (Fig. 2). After the addition of C1-INH the material is enriched in a typical precipitate of the kind that can be produced with anti-IV antibodies. The interactions of the mixed and subunit vaccines with C1-INH become visible with an antiserum to C1-INH. With the resultant increased detection sensitivity it can be seen that C1-INH/IV antigen
30 complexes of varying mobility must lie along the entire migration path.

3. No conspicuous heterogeneities are found in the plasma, even after the addition of vaccine. The complexing of IV components by C1-INH may be an explanation for this (Fig. 8).

4. In each of 4 pools of citrated human plasma we found one complex of C1-INH and one of IV antigens. In the electric field it migrates faster than the vaccine added for comparison purposes. We have evidence that there are more complexes of this kind which are smaller and more mobile than the vaccine (see above) but are at the limit of detection.

5. As we have shown, IV have 2 binding sites for C1-INH: the haemagglutinins and the AC of NA. Both bind to the neuraminic acid groups of C1-INH; the stronger bond is likely to be from the AC of NA; it is formed first; in a solution containing IV and C1-INH, the splitting of neuraminic acid residues is seen to occur much delayed – it is recognizable from the decrease in electrophoretic mobility – and often only from 37°C onwards. This too shows that IV-NA is inhibited by C1-INH. Applied to physiological conditions it can be concluded from this that IV on the mucous membrane is not only bound but also inactivated by C1-INH. It can thus also be assumed that the IV antigen found in the pool plasma by immunoelectrophoresis is not infectious, particularly as we have observed virus complexes only in plasmas which also contained antibodies to the homologous virus. This defence mechanism is impressive because it guarantees that no infectious material gets into circulation. Two plasma proteins see to that: the C1-INH and antibodies to the virus; the two molecules “cooperate”: the C1-INH/IV complex is for example dissociated from the homologous virus antibody and the virus is taken over. These complexes, which probably exist in equilibrium, and their prolonged presence could explain the life-long immunity known to be conferred by, for example, vaccination against measles (Pschyrembel, Klinisches Wörterbuch 257th edition 1994; de Gruyter; p. 941) and against smallpox (Hammarlund E et al.; Nature Medicine 2003; 9: 1131).

Since NA are widespread, particularly in infectious agents, and specifically in viruses and bacteria, the principle of binding, inactivation and immune defence described for IV could have broad biological applications – and therapeutic ones.

5

These properties make C1-INH an important element in the defence against micro-organisms such as infectious viruses. Since the principle is simple, effective and very promising and C1-INH is available as a highly purified protein for intravenous administration, it is an alternative to or at least an addition to the usual adjuvant-
10 vaccine combinations; it can above all be used in cases where it is known that the infectious agent contains neuraminidase (e.g. bacteria) or haemagglutinin and neuraminidase (virus particles such as IV, paramyxoviruses, rotaviruses and perhaps even SARS) as a constituent of its membrane. Given the properties of C1-INH, extravascular administration via the mucous membranes is both useful and
15 conceivable.

Figures

Fig. 1 Detection of IV-specific antigens in an IV vaccine in the Ouchterlony agar gel diffusion test

Middle: IV vaccine (90 µg/ml) and after 24 h

C1-INH solution (125 µg/ml)

In the semi-circle from left;

Pooled citrated human plasma

Anti-C1-INH serum

Immunoglobulin concentrate (batch 1)

Immunoglobulin concentrate (batch 2)

Fig. 2 Characterization of the IV vaccine and IV/INH complex by immunoelectrophoresis in agarose

a) Trough: Immunoglobulin concentrate (batch 1)

b) Trough: Anti-C1-INH serum

1. IV vaccine (5 µg),

2. IV vaccine (5 µg) plus C1-INH (100 µg)

3. C1-INH (100 µg)

All samples in a final volume of 100 µl

Application volume 10 µl, diffusion time 17 h

Fig. 3 Action of neuraminidase on C1-INH and the binding of IV antigens

In each case 500 µl C1-INH (250 µg/ml) were treated with 10 µl test neuraminidase (Dade Behring, QRKD 253670)

and/or

50 µl IV vaccine (4.5 µg):

a) C1-INH,

b) C1-INH plus neuraminidase,

c) C1-INH plus neuraminidase and IV vaccine,
 d) and e) C1-INH plus IV vaccine,
 f) C1-INH/IV complex plus neuraminidase
 Volume made up with physiol. NaCl; incubation for 15 min at room
 temperature

Troughs: Anti-C1-INH serum, application volume 10 μ l; diffusion time 17 h

Fig. 4 Inhibition of IV vaccine binding to C1-INH by a synthetic, specific NA inhibitor: Tamiflu® (Roche)

- a) C1-INH (250 μ g/ml, 100 μ l)
- b) IV vaccine (50 μ l) plus C1-INH
- c) IV vaccine preincubated with Tamiflu® (10 μ g/100 μ l) plus C1-INH
- d) IV vaccine preincubated Tamiflu® plus VC-NA and C1-INH
- e) IV vaccine preincubated with VC-NA plus Tamiflu® and C1-INH

Troughs: Anti-C1-INH serum

All mixtures made up to the same volume; preincubated overnight at
 room temperature and, before immunoelectrophoresis, for 2 h at 37°C
 Application volume 10 μ l, diffusion time 17 h

Fig. 5 Characterization of the VC-NA/C1-INH complex formed after the addition of VC-NA (test neuraminidase) to citrated human plasma

- a) Human plasma diluted 1:2 with phys. NaCl
- b) Human plasma diluted 1:2 with test neuraminidase

Troughs: top anti-C1-INH serum

Bottom anti-inter- α -trypsin inhibitor serum

Application volume 10 μ l, diffusion time 17 h

Fig. 6 Binding of IV antigen to isolated C1-INH (1), to C1-INH in citrated human plasma (2) and in EDTA plasma (3)

- | | | |
|----|--------------------------|---|
| 5 | 1 0.5 ml C1-INH | a) plus 50 μ l physiol. NaCl
b) plus 50 μ l IV vaccine
c) = b) 1 h incubated at 37°C |
| 10 | 2 0.5 ml citrated plasma | a) plus 50 μ l physiol. NaCl
b) plus 50 μ l IV vaccine
c = b) incubated for 1 h at 37°C |
| | 3 0.5 ml EDTA plasma | a) plus 50 μ l physiol. NaCl
b) plus 50 μ l IV vaccine
c = b) incubated for 1 h at 37°C |

Troughs: Anti-C1-INH serum

Application volume: 10 μ l, diffusion time 17 h

Fig. 7 The agar gels in Fig. 4 after staining with Coomassie brilliant blue

Fig. 8 Identification of the IV and its complex in citrated plasma by immunoelectrophoresis

- | | |
|----|---|
| 20 | a) Trough: Immunoglobulin concentrate
b) Trough: Anti-C1-INH serum
1. Pooled citrated human plasma
2. 2.5 μ g IV vaccine in 50 μ l pooled, citrated human plasma |
|----|---|

5 Claims

1. Use of C1-INH to make a drug for therapeutic defence against and neutralization of viruses pathogenic to humans, but possibly also of their toxic components, characterized by the fact that agents pathogenic to humans have
10 membrane constituents with acceptor functions, such as haemagglutinins or neuraminidase or haemagglutinins and neuraminidase.
2. Use as per claim 1, characterized by the fact that the drug is used to alleviate the severity and consequences of acute viral infections such as measles and
15 mumps, or prevents those infections.
3. Use of C1-INH to modulate the immune response, for example as a constituent of human vaccines, to infectious agents that are pathogenic to humans and have membranes containing glycoprotein or glycolipid
20 components, and specifically influenza viruses, paramyxoviruses and rotaviruses with their haemagglutinin components.
4. Use of detection methods for diagnostic purposes, characterized by the fact that the interaction of C1-INH with haemagglutinins is used directly or
25 indirectly.
5. Use of C1-INH or of partial structures of C1-INH to separate off viruses with membrane constituents as acceptors, such as haemagglutinins and/or neuraminidase.
30
6. Therapeutic and diagnostic use of C1-INH as a neuraminidase inhibitor.

1/8




Fig.1

2/8

Fig.2a(1)

Fig.2a(2)





Fig.2b(2)

Fig.2b(3)



3/8




Fig.3

4/8

Fig.4a

6893

Fig.4b

6893

Fig.4b

6894

Fig.4c

6894

Fig.4b

6895

Fig.4d


6895

Fig.4b

6896

Fig.4e

6896



5/8

Fig.5a





Fig.5b



6/8

Fig.6(1)a 6314

Fig.6(1)b 6314

Fig.6(1)a 6315

Fig.6(1)c 6315

Fig.6(2)a 6318

Fig.6(2)b 6318

Fig.6(2)a 6319

Fig.6(2)c 6319

Fig.6(3)a 6320

Fig.6(3)b 6320

Fig.6(3)a 6323

Fig.6(3)c 6323

7/8

Fig.7(1)a

Fig.7(1)b

Fig.7(1)a

Fig.7(1)c

Fig.7(2)a

Fig.7(2)b

Fig.7(2)a


Fig.7(2)c

Fig.7(3)a

Fig.7(3)b

Fig.7(3)a

Fig.7(3)c



8/8

Fig.8a





Fig.8b



A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/57 A61P31/12 A61P31/16

BEST AVAILABLE COPY

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 969 017 A (CENTEON PHARMA GMBH) 5 January 2000 (2000-01-05) column 1, lines 27-30 column 2, line 48 - column 3, line 29	1,2,5,6
X	US 6 242 239 B1 (GROENER ALBRECHT ET AL) 5 June 2001 (2001-06-05) abstract; claims 1,2	1,2,5,6
X	KIRSCHFINK M ET AL: "C1-INHIBITOR: AN ANTI-INFLAMMATORY REAGENT WITH THERAPEUTIC POTENTIAL" EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON,, GB, vol. 2, no. 7, 2001, pages 1073-1083, XP009007955 ISSN: 1465-6566 abstract	6

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

14 December 2004

Date of mailing of the international search report

21/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Escobar Blasco, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/009085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DROUET CHRISTIAN ET AL: "Hepatitis C virus NS3 serine protease interacts with the serpin C1 inhibitor"</p> <p>FEBS LETTERS, vol. 458, no. 3, 24 September 1999 (1999-09-24), pages 415-418, XP002310593 ISSN: 0014-5793 page 418, left-hand column, paragraph 3 page 415, right-hand column, lines 4,5, paragraph 4</p> <p>-----</p>	1,2,6

INTERNATIONAL SEARCH REPORT

International Application No

PC ~~JP~~ P2004/009085

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0969017	A	05-01-2000	DE 19829014 A1	05-01-2000
			AU 766767 B2	23-10-2003
			AU 3686599 A	13-01-2000
			CA 2276564 A1	30-12-1999
			EP 0969017 A1	05-01-2000
			JP 2000044599 A	15-02-2000
			KR 2000006553 A	25-01-2000
			US 2004152635 A1	05-08-2004
US 6242239	B1	05-06-2001	DE 19827750 C1	29-07-1999
			AU 745851 B2	11-04-2002
			AU 3578199 A	06-01-2000
			CA 2276785 A1	23-12-1999
			EP 0966976 A1	29-12-1999
			JP 2000032978 A	02-02-2000
			KR 2000006313 A	25-01-2000
			US 2004152635 A1	05-08-2004

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.